Loading
A next-generation folate-receptor ADC that works even in tumours with low folate receptor, with responses in both ovarian and endometrial cancer.
Ovarian cohort: confirmed ORR 55.6% at 120 mg/m² (n=20) and 22.7% at 100 mg/m² (n=22) with long follow-up; endometrial cohort (n=64, after anti-PD-1 and platinum): ORR 50% at 100 mg/m² including complete responses, earning Breakthrough Therapy designation. Phase 3 RAINFOL-02 in platinum-resistant ovarian cancer is enrolling, with primary completion expected in 2027. Unlike mirvetuximab, benefit is not restricted to FRα-high tumours.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer.
Shares Rinatabart sesutecan, Genmab, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads).
Shares Rinatabart sesutecan, Genmab, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Folate receptor alpha, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Folate receptor alpha, Advanced or recurrent endometrial cancer, Platinum-resistant ovarian cancer, Endometrial cancer.
Shares Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Ovarian cancer.